(0.33%) 5 116.62 points
(0.33%) 38 364 points
(0.38%) 15 989 points
(-0.95%) $83.05
(5.56%) $2.03
(0.30%) $2 354.20
(0.45%) $27.66
(4.10%) $959.90
(-0.26%) $0.932
(-0.44%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors...
Stats | |
---|---|
本日の出来高 | 63 977.00 |
平均出来高 | 114 709 |
時価総額 | 32.20M |
EPS | $0 ( 2024-03-11 ) |
次の収益日 | ( $-0.350 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.620 |
ATR14 | $0.00900 (1.07%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Burcar Melody | Sell | 80 000 | Stock Option (Right to Buy) |
2024-03-20 | Burcar Melody | Sell | 47 500 | Stock Option (Right to Buy) |
2024-03-20 | Burcar Melody | Sell | 33 250 | Stock Option (Right to Buy) |
2024-03-20 | Burcar Melody | Sell | 100 000 | Stock Option (Right to Buy) |
2024-03-12 | Rothera Mark | Buy | 475 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
67.76 |
Last 97 transactions |
Buy: 4 797 715 | Sell: 606 024 |
ボリューム 相関
Sunesis Pharmaceuticals 相関
10 最も負の相関 | |
---|---|
AMRB | -0.931 |
MNKD | -0.915 |
CCRC | -0.915 |
IBEX | -0.907 |
SRAC | -0.904 |
PBFS | -0.903 |
RAVN | -0.901 |
SLGN | -0.898 |
SEDG | -0.896 |
MGI | -0.896 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Sunesis Pharmaceuticals 相関 - 通貨/商品
Sunesis Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-492 000 (0.00 %) |
EPS: | $-1.320 |
FY | 2023 |
収益: | $0 |
総利益: | $-492 000 (0.00 %) |
EPS: | $-1.320 |
FY | 2022 |
収益: | $0 |
総利益: | $-210 000 (0.00 %) |
EPS: | $-1.320 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Sunesis Pharmaceuticals
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。